Prescient Therapeutics Ltd (PTX.AX) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · Australia · ISIN AU000000PTX3

Price
0.05 AUD
Market cap
60.62 m AUD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
-49.31 %
Return on assets (ROA)
-43.01 %

Prescient Therapeutics Ltd financials

Fiscal year20252026
Revenue4.36 m AUD–
Gross profit4.36 m AUD-110,343.00 AUD
Operating income-7.54 m AUD-10.59 m AUD
EBIT-7.54 m AUD-10.59 m AUD
Net income-7.32 m AUD-7.00 m AUD
Diluted EPS – continuing operations-0.01 AUD-0.01 AUD

Full history since 1989, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Prescient Therapeutics Ltd

Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first-in-class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company is also developing cell therapy platforms, including CellPryme, a high-performance cell therapy enhancement platform; and OmniCAR, is a platform seeks to overcome the challenges of conventional CAR-T therapy including manufacturing, safety and reliability. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.